Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112

NCT05970978 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT05970978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05970978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IBI112 in Participants With Psoriasis Who Were Treated With Biologics and Switched to IBI112
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 28, 2023
Completion date
January 26, 2025
Enrollment
152 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis